- Home
- EXEL
EXEL
Exelixis Inc.
as 11-15-2024 4:00pm EST
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 9.7B | IPO Year: | 2000 |
| Target Price: | $31.72 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.55 | EPS Growth: | 441.02 |
| 52 Week Low/High: | $19.20 - $36.60 | Next Earning Date: | 10-29-2024 |
| Revenue: | $2,081,598,000 | Revenue Growth: | 17.31% |
| Revenue Growth (this year): | 20.53% | Revenue Growth (next year): | 1.54% |
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | Nov 5 '24 | Sell | $35.00 | 96,986 | $3,394,510.00 | 498,945 | |
| Hessekiel Jeffrey | EXEL | EVP & General Counsel | Oct 28 '24 | Sell | $28.39 | 25,000 | $709,750.00 | 580,325 | |
| Hessekiel Jeffrey | EXEL | EVP & General Counsel | Sep 23 '24 | Sell | $26.38 | 25,000 | $659,500.00 | 580,325 | |
| Hessekiel Jeffrey | EXEL | EVP, General Counsel & Sec | Aug 26 '24 | Sell | $25.79 | 20,000 | $515,800.00 | 580,325 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
Argus Research
5 days ago
EXEL: Rating increased to a BUY
Zacks
5 days ago
ADMA Biologics Inc (ADMA) Hits Fresh High: Is There Still Room to Run?
Investor's Business Daily
6 days ago
Vericel Stock Sees RS Rating Shoot Higher
Zacks
6 days ago
What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?
Zacks
6 days ago
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
MT Newswires
9 days ago
Exelixis Insider Sold Shares Worth $3,394,510, According to a Recent SEC Filing
Business Wire
10 days ago
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
Zacks
10 days ago
Here's Why Exelixis (EXEL) is a Strong Value Stock
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.